Jim Cramer Skeptical on Pfizer Growth Despite 7% Dividend Yield

Key Facts

As the healthcare sector struggles to regain its post-pandemic momentum, pressure is mounting on Pfizer due to a lack of clear future growth catalysts. Jim Cramer expressed deep skepticism toward the company's stock, stating he cannot identify the specific drivers that will propel future expansion. According to reports, Cramer noted that the major acquisition of Seagen has not yet resolved the core earnings growth problems facing Pfizer, undermining the stock's investment appeal despite its high dividend yield.

These criticisms come as PFE faces significant headwinds compared to industry peers; for instance, Eli Lilly has seen robust growth driven by weight-loss treatments, while Pfizer continues to grapple with declining COVID-19 product revenues. Per market data, Pfizer's current dividend yield of approximately 7% remains one of the highest in the S&P 500, yet Cramer warned that bonds might offer a safer alternative for yield-seeking investors given the uncertainty surrounding the company's financial trajectory.

Regarding market performance, PFE closed at $23.72 (as of July 06, 2026), having traded between a day low of $23.62 and a high of $24.2. Investors are closely monitoring operational updates for any shift in sentiment, while also eyeing broader economic catalysts such as the U.S. ISM Services PMI data, which may provide insights into consumer strength and its indirect impact on the pharmaceutical industry.